{"id":"https://openalex.org/W4240420099","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e15516","title":"Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial.","display_name":"Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial.","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W4240420099","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e15516"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.e15516","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e15516","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e15516","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025382507","display_name":"Noura J. Choudhury","orcid":"https://orcid.org/0000-0002-5980-4973","observed_orcids":["https://orcid.org/0000-0002-5980-4973"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Noura Choudhury","raw_affiliation_strings":["The University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083535108","display_name":"Alexa Campanile","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexa Campanile","raw_affiliation_strings":["The University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047818279","display_name":"James Lloyd Wade","orcid":"https://orcid.org/0000-0002-3802-3860","observed_orcids":["https://orcid.org/0000-0002-3802-3860"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Lloyd Wade","raw_affiliation_strings":["Cancer Care Center of Decatur, Decatur, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Care Center of Decatur, Decatur, IL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024303168","display_name":"Tatjana Antic","orcid":"https://orcid.org/0000-0002-0455-9413","observed_orcids":["https://orcid.org/0000-0002-0455-9413"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tatjana Antic","raw_affiliation_strings":["The University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088131964","display_name":"Walter Michael Stadler","orcid":"https://orcid.org/0000-0002-0435-2527","observed_orcids":["https://orcid.org/0000-0002-0435-2527"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Walter Michael Stadler","raw_affiliation_strings":["University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101940701","display_name":"Yusuke Nakamura","orcid":"https://orcid.org/0009-0009-8461-749X","observed_orcids":["https://orcid.org/0009-0009-8461-749X","https://orcid.org/0000-0002-2310-0587","https://orcid.org/0000-0003-2956-382X","https://orcid.org/0000-0003-4425-4216","https://orcid.org/0009-0004-6320-7030"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yusuke Nakamura","raw_affiliation_strings":["The University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018398274","display_name":"Peter H. O\u2019Donnell","orcid":"https://orcid.org/0000-0003-2650-0049","observed_orcids":["https://orcid.org/0000-0003-2650-0049"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter H. O'Donnell","raw_affiliation_strings":["The University of Chicago, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"e15516","last_page":"e15516"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.923799991607666,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.923799991607666,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.041600000113248825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.026900000870227814,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-urothelial-carcinoma","display_name":"metastatic urothelial carcinoma","score":0.8740000128746033},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.8799999952316284},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.871999979019165},{"id":"https://openalex.org/keywords/her3","display_name":"HER3","score":0.9850000143051147},{"id":"https://openalex.org/keywords/erbb4","display_name":"ErbB4","score":0.8550000190734863},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.800000011920929},{"id":"https://openalex.org/keywords/platinum-refractory-disease","display_name":"platinum-refractory disease","score":0.8270000219345093},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.4560000002384186},{"id":"https://openalex.org/keywords/copy-number-variation","display_name":"copy number variation","score":0.6970000267028809},{"id":"https://openalex.org/keywords/her2-amplification","display_name":"HER2 amplification","score":0.6010000109672546},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.722000002861023},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6940000057220459},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.46799999475479126}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8907814025878906},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.8410585522651672},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6570857763290405},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5536141395568848},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5362927317619324},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5138945579528809},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.49741604924201965},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45744985342025757},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4444781243801117},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4270933270454407},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3503795266151428},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.31099510192871094},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.2636062800884247},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.1935095191001892},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.09880334138870239}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.e15516","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.e15516","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.e15516","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.6299999952316284,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2590068517","https://openalex.org/W2341548114","https://openalex.org/W2789349347","https://openalex.org/W2942914316","https://openalex.org/W4242888240","https://openalex.org/W2763687273","https://openalex.org/W4389784708","https://openalex.org/W4286297061","https://openalex.org/W4379282598","https://openalex.org/W2093295319"],"abstract_inverted_index":{"e15516":[0],"Background:":[1],"Platinum-refractory":[2],"UC":[3,30,70,336],"has":[4,51,199],"a":[5,331],"dismal":[6],"prognosis,":[7],"with":[8,67,97,217,231,242,286,305],"no":[9],"FDA-approved":[10],"second-line":[11],"therapies.":[12,38],"Somatic":[13],"mutations":[14],"and":[15,25,31,113,123,169,224,239,247],"copy":[16],"number":[17],"(CN)":[18],"variation":[19],"in":[20,29,54,76,141,145,151,155,212,274,284,302,337],"EGFR":[21],"(ErbB1),":[22],"HER2":[23,221,246,309],"(ErbB2),":[24],"ErbB3":[26,233,249,311,317],"are":[27],"frequent":[28],"may":[32],"represent":[33],"viable":[34],"targets":[35],"for":[36,109,226,236,291,334],"novel":[37],"We":[39],"aimed":[40],"to":[41,261,279,318],"investigate":[42],"whether":[43],"afatinib,":[44],"an":[45],"oral,":[46],"irreversible":[47],"Erb":[48,213],"family":[49],"blocker,":[50],"clinical":[52],"benefit":[53],"metastatic":[55,78],"UC.":[56],"Methods:":[57],"In":[58],"this":[59],"single":[60],"arm,":[61],"phase":[62],"II":[63],"trial,":[64],"patients":[65],"(pts)":[66],"unresectable":[68],"platinum-refractory":[69,303],"who":[71],"received":[72,80],"\u2264":[73],"1":[74,144,178,197,215,229,240],"chemotherapy":[75,161],"the":[77,173,269],"setting":[79],"afatinib":[81,319,329],"40":[82],"mg/day":[83],"continuously":[84],"until":[85],"disease":[86],"progression":[87],"or":[88],"intolerable":[89],"toxicity.Primary":[90],"endpoint":[91],"was":[92,115,281],"3-month":[93],"progression-free":[94],"survival":[95],"(PFS3),":[96],"drug":[98],"deemed":[99],"promising":[100],"if":[101],"\u2265":[102],"42%":[103],"pts":[104,186,285,292],"had":[105,188,209,272],"PFS3.":[106],"Pre-specified":[107],"analysis":[108,125],"EGFR,":[110],"HER2,":[111],"ErbB3,":[112],"ErbB4":[114],"conducted":[116],"using":[117],"targeted":[118],"next-generation":[119],"sequencing":[120],"(Life":[121],"Technologies)":[122],"CN":[124],"(Taqman).":[126],"Results:":[127],"15":[128],"ptshave":[129],"enrolled:":[130],"median":[131,157],"age":[132],"66":[133],"(44-78),":[134],"11":[135],"M/4":[136],"F,":[137],"ECOG":[138],"PS":[139,143],"0":[140],"20%,":[142,152],"80%,":[146],"Hb":[147],"<":[148],"10":[149,270],"g/dl":[150],"liver":[153],"metastases":[154],"13%,":[156],"time":[158],"from":[159],"prior":[160],"=":[162,296],"4.4":[163],"mo.":[164],"Rash":[165],"(73%),":[166],"diarrhea":[167],"(33%),":[168],"fatigue":[170],"(13%)":[171],"were":[172],"most":[174],"common":[175],"drug-related":[176],"toxicities;":[177],"pt":[179,198,216,230,241],"required":[180],"dose-reduction":[181],"(grade":[182],"3":[183,202,207],"fatigue).":[184],"3/14":[185],"(21%)":[187],"PFS3":[189],"(1":[190],"partial":[191],"response":[192],"(PR),":[193],"2":[194],"stable":[195],"disease);":[196],"not":[200],"reached":[201],"mo":[203,259,283],"on":[204,253],"therapy.":[205],"All":[206],"responders":[208,307],"molecular":[210,287],"alterations":[211,273,288,294],"genes:":[214],"4":[218],"copies":[219,244],"of":[220,245,268,316,328],"achieved":[222],"PR":[223],"responded":[225,235],"6.9":[227],"mo;":[228,238],"Gly284Arg":[232],"mutation":[234,250],"7":[237],"73":[243],"Arg103Gly":[248],"never":[251],"progressed":[252],"therapy,":[254],"but":[255],"discontinued":[256],"after":[257],"10.3":[258],"due":[260],"depressed":[262],"left":[263],"ventricular":[264],"ejection":[265],"fraction.":[266],"None":[267],"non-responders":[271],"these":[275],"four":[276],"genes.":[277],"Time":[278],"progression/discontinuation":[280],"8.1":[282],"vs.":[289],"1.8":[290],"without":[293],"(p":[295],"0.02).":[297],"Conclusions:":[298],"Afatinib":[299],"demonstrates":[300],"activity":[301],"UC,":[304],"all":[306],"bearing":[308],"and/or":[310],"alterations.":[312],"The":[313],"potential":[314,332],"contribution":[315],"sensitivity":[320],"is":[321],"novel.":[322],"These":[323],"data":[324],"support":[325],"ongoing":[326],"testing":[327],"as":[330],"therapy":[333],"refractory":[335],"marker-selected":[338],"pts.":[339],"Clinical":[340],"trial":[341],"information:":[342],"NCT02122172.":[343]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2022-05-12T00:00:00"}